PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT00349921: Clonidine Versus Adenosine to Treat Neuropathic Pain
Official title: Clonidine Versus Adenosine to Treat Neuropathic Pain
Conditions: Pain
Summary: The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
Interventions:
description: Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
name: clonidine
other_name: duraclon
type: Drug
description: Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
name: adenosine
type: Drug
description: inactive substance
name: placebo
other_name: dummy
type: Drug
description: inactive substance
name: placebo
other_name: dummy
type: Drug
Study arms:
design_group_description: clonidine given in first injection adenosine given in second injection
design_group_title: clonidine first, then adenosine
design_group_type: Active Comparator
design_group_description: adenosine given in first injection clonidine given in second injection
design_group_title: adenosine first, then clonidine
design_group_type: Active Comparator
design_group_description: placebo
design_group_title: clonidine given first, then placebo
design_group_type: Placebo Comparator
design_group_description: placebo
design_group_title: adenosine given first, then placebo
design_group_type: Placebo Comparator
Sponsor: Wake Forest School of Medicine
Collaborators: National Institute of Neurological Disorders & Stroke
Drug name mappings:
name: 盐酸可乐定
lang: CN
name: Clonidine Hydrochloride
lang: EN
name: クロニジン塩酸塩
lang: JP
name: 腺苷
lang: CN
name: Adenosine
lang: EN
name: アデノシン
lang: JP
Clinical trial NCT01948128: Effects of Vitamin D in Patients With Breast Cancer
Official title: A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Vitamin D in Patients With Breast Cancer. The ICARUS Trial
Conditions: Breast Cancer
Summary: This protocol is a randomized, phase 2 "window of opportunity" trial assessing the biological effects of short term oral vitamin D administration on breast cancer clinical and translational markers in patients awaiting surgery at the Ottawa Hospital. It takes advantage of the current wait times (2-8 weeks) for breast cancer surgery as a "window of opportunity" to rapidly assess biological changes with vitamin D intake.
Interventions:
description: Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
name: Vitamin D3
other_name: Vitamin D
cholecalciferol
type: Drug
description: Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
name: Placebo
type: Other
Study arms:
design_group_description: Vitamin D3 40,000 iu per day by mouth
design_group_title: Vitamin D3
design_group_type: Experimental
design_group_description: Placebo taken daily by mouth
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Ottawa Hospital Research Institute
Collaborators: The Canadian Breast Cancer Foundation
Drug name mappings:
name: 维生素D3
lang: CN
name: Colecalciferol
lang: EN
Clinical trial NCT04483115: Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension
Official title: Multi-center, Randomized，Placebo and Positive Controlled Clinical Study of TPN171H Tablets on Acute Haemodynamics in Patients with Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension
Summary: This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each group 10 cases.
Interventions:
description: Tablets; Oral; Single dose
name: TPN171H
other_name: Simmerafil
type: Drug
description: Tablets; Oral; Single dose
name: Placebo
type: Drug
description: Tablets; Oral; Single dose
name: Tadalafil
other_name: ADCIRCA
type: Drug
Study arms:
design_group_description: TPN171H 2.5mg tablet + Placebo 10mg tablet
design_group_title: TPN171H 2.5mg group
design_group_type: Experimental
design_group_description: TPN171H 5mg tablet + Placebo 10mg tablet
design_group_title: TPN171H 5mg group
design_group_type: Experimental
design_group_description: TPN171H 10mg tablet + Placebo 5mg tablet
design_group_title: TPN171H 10mg group
design_group_type: Experimental
design_group_description: Placebo 5mg tablet+ Placebo 10mg tablet
design_group_title: Placebo group
design_group_type: Placebo Comparator
design_group_description: tadalafil tablet 20mg
design_group_title: tadalafil 20mg group
design_group_type: Active Comparator
design_group_description: tadalafil tablets 20mg *2
design_group_title: tadalafil 40mg group
design_group_type: Active Comparator
Sponsor: Suzhou Vigonvita Life Sciences Co.,Ltd
Collaborators: Shanghai Institute of Materia Medica Chinese Academy of Sci
Drug name mappings:
name: 盐酸司美那非
lang: CN
name: Simenafil Hydrochloride
lang: EN
Clinical trial NCT02248597: Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Official title: Haploidentical Stem Cell Transplant Using Post Transplant Cyclophosphamide for GvHD Prophylaxis: A Pilot Study
Conditions: Graft Versus Host Disease
Hematopoietic/Lymphoid Cancer
Summary: This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cyclophosphamide after the transplant may stop this from happening.
Interventions:
description: Given IV
name: fludarabine phosphate
other_name: 2-F-ara-AMP
Beneflur
Fludara
type: Drug
description: Given IV
name: busulfan
other_name: BSF
BU
Misulfan
Mitosan
Myeloleukon
type: Drug
description: Given IV
name: cyclophosphamide
other_name: CPM
CTX
Cytoxan
Endoxan
Endoxana
type: Drug
description: Undergo myeloablative or reduced intensity allogeneic stem cell transplant
name: allogeneic hematopoietic stem cell transplantation
type: Procedure
name: tacrolimus
other_name: FK 506
Prograf
type: Drug
name: mycophenolate mofetil
other_name: Cellcept
MMF
type: Drug
Study arms:
design_group_description: PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2<br/>TRANSPLANT: Patients undergo stem cell transplant on day 0.<br/>GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation
design_group_title: Treatment (stem cell transplant with GVHD prophylaxis)
design_group_type: Experimental
Sponsor: Wake Forest School of Medicine
Collaborators: National Cancer Institute
Drug name mappings:
name: 白消安
lang: CN
name: Busulfan
lang: EN
name: ブスルファン
lang: JP
name: 磷酸氟达拉滨
lang: CN
name: Fludarabine Phosphate
lang: EN
name: フルダラビンリン酸エステル
lang: JP
name: 环磷酰胺
lang: CN
name: Cyclophosphamide
lang: EN
name: シクロホスファミド水和物
lang: JP
name: 他克莫司
lang: CN
name: Tacrolimus
lang: EN
name: タクロリムス水和物
lang: JP
name: 吗替麦考酚酯
lang: CN
name: Mycophenolate Mofetil
lang: EN
name: ミコフェノール酸 モフェチル
lang: JP
Clinical trial NCT07412171: NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC
Official title: NECTAR Study: A Multicenter, Open-label, Randomized Phase II Study of Neoadjuvant Toripalimab Plus 9MW2821 Versus Upfront Radical Nephroureterectomy With/Without Lymph Node Dissection in Patients With Local Upper Tract Urothelial Carcinoma (UTUC)
Conditions: Upper Tract Urothelial Carcinoma
Summary: The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).
In this study, eligible participants will be randomly assigned to receive either neoadjuvant treatment with toripalimab plus the investigational drug 9MW2821 followed by radical nephroureterectomy with or without lymph node dissection, or upfront radical nephroureterectomy with or without lymph node dissection as standard of care. The purpose of the study is to compare the pathologic response at the time of surgery between the two treatment approaches and to assess treatment safety.
Participants will be monitored throughout treatment and follow-up for treatment response, adverse events, and other clinical outcomes. The information obtained from this study may help improve future treatment strategies for patients with localized UTUC.
Interventions:
description: Toripalimab is administered intravenously at a dose of 240 mg every 3 weeks for 3 cycles as neoadjuvant therapy prior to surgery.
name: Toripalimab
type: Drug
description: 9MW2821 is administered intravenously at a dose of 1.25 mg/kg on Day 1 and Day 8 every 3 weeks for 3 cycles as neoadjuvant therapy.
name: 9MW2821
type: Drug
description: Participants undergo radical nephroureterectomy with or without lymph node dissection according to institutional standard of care.
name: Radical Nephroureterectomy with or without Lymph Node Dissection
type: Procedure
Study arms:
design_group_description: Participants receive neoadjuvant toripalimab plus 9MW2821 followed by radical nephroureterectomy with or without lymph node dissection.
design_group_title: Neoadjuvant Toripalimab + 9MW2821
design_group_type: Experimental
design_group_description: Participants undergo upfront radical nephroureterectomy with or without lymph node dissection according to standard of care.
design_group_title: Upfront Surgery (SOC)
design_group_type: Active Comparator
Sponsor: Peking University Third Hospital
Collaborators: Beijing Tumor Hospital
Beijing Friendship Hospital
The First Affiliated Hospital of Zhengzhou University
Jiangsu Provincial People's Hospital
Drug name mappings:
name: 特瑞普利单抗
lang: CN
name: Toripalimab
lang: EN
name: Bulumtatug fuvedotin
lang: EN
Clinical trial NCT00242333: A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD
Official title: A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD.
Conditions: COPD
Summary: The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).
Interventions:
name: AD 237
type: Drug
Study arms:
Sponsor: Sosei Co. Ltd.
Collaborators: Novartis AG
Drug name mappings:
name: 格隆溴铵
lang: CN
name: Glycopyrrolate
lang: EN
name: グリコピロニウム臭化物
lang: JP
Clinical trial NCT01910246: Cardiovascular Effects of Metformin on Obesity
Official title: Cardiovascular Effects of Metformin on Obesity With Subclinical Myocardial Dysfunction
Conditions: Insulin Resistance
Summary: It has been shown that asymptomatic obese adolescents can demonstrate abnormal regional myocardial contraction, with preserved global cardiac function. Metformin has been shown to decrease cardiovascular mortality in patients with type 2 diabetes and insulin resistance, but the mechanism of cardiovascular protection is unknown.
The purpose of this study is to evaluate the reversibility of subclinical cardiovascular abnormalities in obese adolescents with insulin resistance after a six-month course of Metformin. The investigators hypothesized that the beneficial effects of Metformin will be progressive and sustained after six months of therapy.
Interventions:
name: Metformin
type: Drug
Study arms:
design_group_description: Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
design_group_title: Metformin, Insulin Resistance, Cardiac Function,
design_group_type: Experimental
Sponsor: The University of California, San Francisco
Collaborators: US Department of Veterans Affairs (District of Columbia)
Drug name mappings:
name: 盐酸二甲双胍
lang: CN
name: Metformin Hydrochloride
lang: EN
name: メトホルミン塩酸塩
lang: JP
Clinical trial NCT04743622: Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost
Official title: Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients
Conditions: Glaucoma
Ocular Hypertension
Summary: Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study
Interventions:
description: preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes
name: Monoprost
other_name: Preservative-free latanoprost
type: Drug
description: preserved latanoprost 1 drop once a day for 12 weeks to target eyes
name: Xalatan
other_name: Preserved latanoprost
type: Drug
Study arms:
design_group_description: latanoprost : 1 drop once a day for 12 weeks to target eyes
design_group_title: Monoprost (preservative-free latanoprost eye drop)
design_group_type: Experimental
design_group_description: latanoprost : 1 drop once a day for 12 weeks to target eyes
design_group_title: Xalatan (preserved latanoprost eye drop)
design_group_type: Active Comparator
Sponsor: CHA University
Collaborators: SAMIL PHARMACEUTICAL Co., Ltd.
Drug name mappings:
name: 拉坦前列素
lang: CN
name: Latanoprost
lang: EN
name: ラタノプロスト
lang: JP
Clinical trial NCT00516113: A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
Official title: A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine When Used for the Treatment of Premenstrual Dysphoria
Conditions: Premenstrual Dysphoric Disorder
Premenstrual Syndrome
Summary: The objective of this study is to explore the onset of action when serotonin reuptake inhibitors are used to treat premenstrual dysphoric disorder
Interventions:
description: Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
name: paroxetine
type: Drug
Study arms:
design_group_description: Paroxetine 20mg during the luteal phase of the menstrual cycle
design_group_title: 1
design_group_type: Active Comparator
design_group_description: Placebo during the luteal phase of the menstrual cycle
design_group_title: 2
design_group_type: Placebo Comparator
Sponsor: Karolinska Institutet
Collaborators: GSK Plc
Novo Nordisk A/S
University of Gothenburg
Drug name mappings:
name: 盐酸帕罗西汀
lang: CN
name: Paroxetine Hydrochloride
lang: EN
name: パロキセチン塩酸塩水和物
lang: JP
Clinical trial NCT00281606: A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
Official title: A Phase IV, Randomized, Open-label Study of the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
Conditions: HIV Infection
Summary: Guidelines have continued to list lopinavir/ritonavir as a preferred protease inhibitor-containing regimen for HIV-infected individuals. There has recently been increasing interest in once daily therapy. While lopinavir/ritonavir has recently been approved as a once daily therapy it was associated with considerable diarrhea in those treated with soft gel capsules. It is the hope that alternative formulations of lopinavir/ritonavir may provide similar pharmacokinetics with improved tolerability. This includes the possibility of using liquid or newly released tablets. This study will treat people tolerating their current regimen with up to four weeks of each formulation with several assessments of pharmacokinetics and tolerability for each.
Interventions:
description: CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
name: Different formulations of once-daily lopinavir/ritonavir
other_name: Lopinavir/Ritonavir (LPV/r)
type: Drug
Study arms:
design_group_description: Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
design_group_title: LPV/r (800/200 mg) 10 ml liquid
design_group_type: Active Comparator
design_group_description: Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
design_group_title: LPV/r (800/200 mg) 6 gel capsules
design_group_type: Active Comparator
Sponsor: University of California San Diego
Collaborators: Abbott Laboratories
Drug name mappings:
name: 洛匹那韦/利托那韦
lang: CN
name: Lopinavir/Ritonavir
lang: EN
name: ロピナビル/リトナビル
lang: JP
Clinical trial NCT02753283: Preventing Osteoporosis Using Denosumab
Official title: Sustaining Skeletal Health in Frail Elderly
Conditions: Osteoporosis, Postmenopausal
Osteoporosis
Osteoporotic Fractures
Summary: The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.
Interventions:
description: Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
name: denosumab
other_name: Prolia
type: Drug
description: Semi-annual saline injection
name: Placebo
type: Drug
description: Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
name: Calcium and Vitamin D
type: Dietary Supplement
Study arms:
design_group_description: Semi-annual dose for women: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).
design_group_title: Women Denosumab
design_group_type: Experimental
design_group_description: Semi-annual for women: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements).
design_group_title: Women Placebo Group
design_group_type: Placebo Comparator
design_group_description: Semi-annual dose for men: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).
design_group_title: Men Denosumab
design_group_type: Experimental
design_group_description: Semi-annual for men: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements)
design_group_title: Men Placebo Group
design_group_type: Placebo Comparator
Sponsor: University of Pittsburgh
Collaborators: National Institute on Aging
National Institutes of Health
Drug name mappings:
name: 地舒单抗
lang: CN
name: Denosumab
lang: EN
name: デノスマブ（遺伝子組換え）
lang: JP
Clinical trial NCT04582305: Bleomycin Jet Injections in Keloids
Official title: Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design
Conditions: Keloid
Summary: This is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design, in which selected keloids will receive three consecutive treatments of a) bleomycin and b) placebo (saline (NaCl 0,9%)), administered with an electronic pneumatic jet injector.
Interventions:
description: Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
name: Bleomycin
type: Drug
description: Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
name: Normal saline
type: Drug
Study arms:
design_group_description: This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of bleomycin per treatment will be 2 mL, corresponding to 2 USP-E (units) of bleomycin. The maximum cumulative dosage of bleomycin will be 6 USP-E in this study.
design_group_title: Bleomycin jet-injections
design_group_type: Active Comparator
design_group_description: This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be given per 1 cm2, with a maximum of 20 injections per treatment. The maximum dosage of normal saline per treatment will be 2 mL.
design_group_title: Placebo jet-injections
design_group_type: Placebo Comparator
Sponsor: Erasmus Universitair Medisch Centrum Rotterdam
Collaborators: Centre for Human Drug Research
Drug name mappings:
name: 盐酸博莱霉素
lang: CN
name: Bleomycin Hydrochloride
lang: EN
name: ブレオマイシン塩酸塩
lang: JP